Table 2.

Key design features of the NordICC trial on the effects of the offer of screening colonoscopy on CRC risk and mortality

Design	Pragmatic randomized clinical trial
Intervention	Invitation to a single sceening colonoscopy vs. no invitation
Primary endpoint	CRC risk and CRC mortality after median follow-up of 10–15 years
Secondary endpoints	All-cause mortality after median follow-up of 10–15 years
Study population	Men and women aged 55–64 years with no prior CRC and no prior CRC screening
Countries	Poland, Norway, Sweden, the Netherlands^a
Recruitment	2009–2014
Randomization	1 (invited, N = 31,589) to 2 (usual-care, N = 63,370) ratio
Study population included in publication of 10-year results	Total N = 84,585, Invited N = 28,220, Unsual Care N = 56,365; Total N by country: Poland 54,258; Norway 26,411; Sweden 3646
Use of screening offer	42% (ranging from 33% in Poland to 61% in Norway)
Follow-up	Through cancer and population registries
Publication of 10-year results	October 2022
Closing date of follow-up	Not reported

CRC colorectal cancer

^aData from the Netherlands not included in the 2022 report of 10-year follow-up results due to confidentiality issues